阿加曲班对于急性进展性脑梗死的临床疗效  

Clinical Efficacy of Argatroban in the Treatment of Acute Progressive Cerebral Infarction

作　　者：高红哲 GAO Hongzhe(Haicheng Central Hospital,Haicheng 114200,China)

机构地区：[1]海城市中心医院,辽宁海城114200

出　　处：《中国医药指南》2020年第33期82-83,共2页Guide of China Medicine

摘　　要：目的探讨阿加曲班在急性进展性脑梗死临床治疗的应用疗效。方法选取我院2017年1月至2018年12月收治的68例急性进展性脑梗死患者(发病24 h)作为研究对象,分为观察组(阿加曲班+常规治疗)和对照组(常规治疗)各34例,观察两组患者的治疗恢复情况。结果与对照组相比,治疗后观察组患者的治疗有效率(97.06%>76.47%)、Fugl-Meyer运动功能(FMA)评分[(67.2±3.89)分>(55.61±3.53)分]和日常生活活动功能(ADL)评分[(66.13±5.64)分>(56.93±4.38)分]相对更高(P<0.05),而神经功能缺损程度(NIHSS)评分[(14.11±2.85)分<(18.07±3.52)分]相对更低(P<0.05)。结论阿加曲班的应用能够有效治疗急性进展性脑梗死,控制病情的进展和恶化,进而降低疾病风险,加快其康复进程。Objective To investigate the therapeutic effect of argatroban in the clinical treatment of acute progressive cerebral infarction.Methods A total of 68 patients with acute progressive cerebral infarction(24 h onset)who were admitted to our hospital from January 2017 to December 2018 were selected as the research objects and divided into observation group(argatroban+conventional treatment)and control group(conventional treatment)34 cases in each group,observe the treatment recovery of the two groups of patients.Results Compared with the control group,after treatment the treatment efficiency of the observation group(97.06%>76.47%)and Fugl-Meyer motor function(FMA)score[(67.2±3.89)points>(55.61±3.53)points]and the Activity of Daily Living function(ADL)score[(66.13±5.64)points>(56.93±4.38)points]were relatively higher(P<0.05),and the degree of neurological deficit(NIHSS)scores[(14.11±2.85)points<(18.07±3.52)minutes]was relatively lower(P<0.05).Conclusion The application of argatroban can effectively treat acute progressive cerebral infarction,control the progression and deterioration of the disease,thereby reducing the risk of disease and speeding up the recovery process.

关 键 词：急性进展性脑梗死 阿加曲班 临床疗效 神经功能 日常生活活动功能 

分 类 号：R743.33[医药卫生—神经病学与精神病学]